Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc. BofA…
Aimmune Therapeutics’ $176 million Stake Offering
Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc. BofA…